Top

Published in:

01-11-2013 | Original Article

Autosomal recessive hereditary spastic paraplegia—clinical and genetic characteristics of a well-defined cohort

Authors: G. Yoon, B. Baskin, M. Tarnopolsky, K. M. Boycott, M. T. Geraghty, E. Sell, S. Goobie, W. Meschino, B. Banwell, P. N. Ray

Published in: Neurogenetics | Issue 3-4/2013

Abstract

We describe the clinical and genetic features of a well-characterized cohort of patients with autosomal recessive hereditary spastic paraplegia (ARHSP) in the province of Ontario. Patients with documented corticospinal tract abnormalities were screened by whole gene sequencing and multiplex ligation probe amplification for mutations in nine genes known to cause ARHSP. Of a cohort of 39 patients, a genetic diagnosis was established in 17 (44 %) and heterozygous mutations were detected in 8 (21 %). Mutations were most frequent in SPG7 (12 patients), followed by SPG11 (10 patients), PNPLA6 (SPG39, 2 patients), and ZFYVE26 (SPG15, 2 patients). Although there are associations between some clinical manifestations of ARHSP and specific genes, many patients are tested at an early stage of the disease when phenotype/genotype correlations are not obvious. Accurate molecular characterization of well-phenotyped cohorts of patients will be essential to establishing the natural history of these rare degenerative disorders to enable future clinical trials.

Available only for authorised users

Finsterer J, Löscher W, Quasthoff S, Wanschitz J, Auer-Grumbach M, Stevanin G (2012) Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci 318(1–2):1–18PubMedCrossRef

Fink JK (2006) Hereditary spastic paraplegia. Curr Neurol Neurosci Rep 6(1):65–76PubMedCrossRef

Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM (2009) Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain 132(Pt 6):1577–1588PubMedCrossRef

Boukhris A, Stevanin G, Feki I et al (2009) Tunisian hereditary spastic paraplegias: clinical variability supported by genetic heterogeneity. Clin Genet 75(6):527–536PubMedCrossRef

Richards CS, Bale S, Bellissimo DB et al (2007) Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 10(4):294–300CrossRef

Guidubaldi A, Piano C, Santorelli FM et al (2011) Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism. Mov Disord 26(3):553–556PubMedCrossRef

Rainier S, Bui M, Mark E et al (2008) Neuropathy target esterase gene mutations cause motor neuron disease. Am J Hum Genet 82(3):780–5PubMedCrossRef

Noreau A, Dion PA, Szuto A et al (2012) CYP7B1 mutations in French–Canadian hereditary spastic paraplegia subjects. Can J Neurol Sci 39(1):91–94PubMed

Arnoldi A, Crimella C, Tenderini E et al (2012) Clinical phenotype variability in patients with hereditary spastic paraplegia type 5 associated with CYP7B1 mutations. Clin Genet 81(2):150–157PubMedCrossRef

10.

Sánchez-Ferrero E, Coto E, Beetz C et al (2012) SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clin Genet. doi:10.1111/j.1399-0004.2012.01896.x [Epub ahead of print]PubMed

11.

Hehr U, Bauer P, Winner B et al (2007) Long-term course and mutational spectrum of spatacsin-linked spastic paraplegia. Ann Neurol 62(6):656–665PubMedCrossRef

12.

Stevanin G, Santorelli FM, Azzedine H et al (2007) Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet 39(3):366–372PubMedCrossRef

13.

Arnoldi A, Tonelli A, Crippa F et al (2008) A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Hum Mutat 29(4):522–531PubMedCrossRef

14.

Stevanin G, Azzedine H, SPATAX consortium, Denora P et al (2008) Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain 131(Pt 3):772–784PubMedCrossRef

15.

Hanein S, Martin E, Boukhris A et al (2008) Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet 82(4):992–1002PubMedCrossRef

16.

Denora PS, Muglia M, Casali C et al (2009) Spastic paraplegia with thinning of the corpus callosum and white matter abnormalities: further mutations and relative frequency in ZFYVE26/SPG15 in the Italian population. J Neurol Sci 277(1–2):22–25PubMedCrossRef

17.

Orlén H, Melberg A, Raininko R et al (2009) SPG11 mutations cause Kjellin syndrome, a hereditary spastic paraplegia with thin corpus callosum and central retinal degeneration. Am J Med Genet B Neuropsychiatr Genet 150B(7):984–992PubMedCrossRef

18.

Anheim M, Lagier-Tourenne C, Stevanin G et al (2009) SPG11 spastic paraplegia. A new cause of juvenile parkinsonism. J Neurol 256(1):104–108PubMedCrossRef

19.

Southgate L, Dafou D, Hoyle J et al (2010) Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish. Neurogenet 11(4):379–89CrossRef

20.

Liao SS, Shen L, Du J et al (2008) Novel mutations of the SPG11 gene in hereditary spastic paraplegia with thin corpus callosum. J Neurol Sci 275(1–2):92–9PubMedCrossRef

21.

Denora PS, Schlesinger D, Casali C et al (2009) Screening of ARHSP-TCC patients expands the spectrum of SPG11 mutations and includes a large scale gene deletion. Hum Mutat 30(3):E500–19PubMedCrossRef

22.

Schlipf NA, Schüle R, Klimpe S et al (2011) Amplicon-based high-throughput pooled sequencing identifies mutations in CYP7B1 and SPG7 in sporadic spastic paraplegia patients. Clin Genet 80(2):148–60PubMedCrossRef

23.

Tzoulis C, Denora PS, Santorelli FM, Bindoff LA (2008) Hereditary spastic paraplegia caused by the novel mutation 1047insC in the SPG7 gene. J Neurol 255(8):1142–4PubMedCrossRef

24.

Bonn F, Pantakani K, Shoukier M et al (2010) Functional evaluation of paraplegin mutations by a yeast complementation assay. Hum Mutat 31(5):617–21PubMed

25.

Lee MJ, Cheng TW, Hua MS et al (2008) Mutations of the SPG11 gene in patients with autosomal recessive spastic paraparesis and thin corpus callosum. J Neurol Neurosurg Psychiatry 79(5):607–9PubMedCrossRef

Title: Autosomal recessive hereditary spastic paraplegia—clinical and genetic characteristics of a well-defined cohort
Authors: G. Yoon
B. Baskin
M. Tarnopolsky
K. M. Boycott
M. T. Geraghty
E. Sell
S. Goobie
W. Meschino
B. Banwell
P. N. Ray
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Neurogenetics / Issue 3-4/2013
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-013-0366-9

At a glance: The STEP trials

Springer Medicine

Autosomal recessive hereditary spastic paraplegia—clinical and genetic characteristics of a well-defined cohort

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2013

Benign infantile convulsions (IC) and subsequent paroxysmal kinesigenic dyskinesia (PKD) in a patient with 16p11.2 microdeletion syndrome

Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington’s disease motor onset

Brachial amyotrophic diplegia associated with the a140a superoxide dismutase 1 mutation

Diagnostic utility of whole exome sequencing in patients showing cerebellar and/or vermis atrophy in childhood

Neuroligin modulates the locomotory dopaminergic and serotonergic neuronal pathways of C. elegans

Chromosomal rearrangements in Tourette syndrome: implications for identification of candidate susceptibility genes and review of the literature